QS-7 Biosynthetic Route for Scalable Hexasaccharide Assembly
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for synthesizing QS-7 molecule rely on purification from the native Quillaja saponaria plant, which is limited and does not address the need for efficient production of QS-7 precursors and variants with specific immunostimulatory properties.
Innovation Solution
A biosynthetic route is developed to form a branched acetylated hexasaccharide at the C-28 position of the QS-7 molecule by attaching a glucose residue at the C-3 position of the rhamnose residue, a rhamnose residue at the C-3 position of the D-fucose, and an acetyl moiety at the C-4 position of the D-fucose, using specific enzymes and host cells to produce QS-7 and its precursors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If purification from native Quillaja saponaria plant is used, then QS-7 molecule can be obtained, but production efficiency is limited and scaling is difficult
Solution Approach 1:
The patent applies copying by transferring the biosynthetic pathway from the native plant to a heterologous host system (yeast or cell culture). The enzymatic steps for synthesizing the branched acetylated hexasaccharide are replicated in the host, enabling scalable production without relying on limited plant material. This allows the complex saponin synthesis to be reproduced in a controllable, amplifiable system.
Solution Approach 2:
The patent replaces the mechanical extraction and purification process from plant tissue with a biochemical synthesis approach. Instead of mechanically harvesting and chemically purifying QS-7 from plant bark, the invention uses enzymatic reactions in a controlled biological system to synthesize the molecule, enabling more efficient and scalable production.
2Reliability
If plant-based purification is used, then QS-7 with immunostimulatory properties is obtained, but cost-effectiveness is poor and production is inefficient
Solution Approach 1:
The patent applies parameter changes by modifying the biosynthetic pathway parameters in the host system. The enzymatic conditions, substrate availability, and reaction parameters are optimized to produce QS-7 with the same immunostimulatory properties as the plant-derived version, while achieving superior production efficiency and cost-effectiveness through controlled biochemical synthesis.
3Productivity
If biosynthetic route is developed, then production efficiency is improved, but process complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex biosynthetic pathway into discrete enzymatic steps, each catalyzed by a specific enzyme. The synthesis of the branched acetylated hexasaccharide is broken down into individual transformations (糖基转移, 乙酰化), allowing each step to be optimized independently and facilitating modular assembly of the complete pathway in the host system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the efficient production of QS-7 and its precursors, providing a cost-effective and scalable alternative to plant-based purification, while maintaining the immunostimulatory properties essential for vaccine adjuvants.
Implementation Method 1
enzymes involved in the methods, vectors, host cells and biological systems to produce the products
Implementation Method 2
attaching a glucose residue at the C-3 position of the rhamnose residue, a rhamnose residue at the C-3 position of the D-fucose, and an acetyl moiety at the C-4 position of the D-fucose
Data Source
AI summary
The present invention relates to a biosynthetic route to precursors of the QS-7 molecule, as well as routes to make the QS-7 molecule, enzymes involved, the products produced and uses of the product.